MK-7480 Single Ascending Dose Study in Healthy Participants
This research is a very early study, called a Phase 1 trial, and it's the first time the new medicine, MK-7480, is being given to people. The main aim is to understand if MK-7480 is safe for healthy men and what happens to the medicine in their bodies after they take it. Researchers will give different men a single, increasing dose of the medicine to see how well it's tolerated. This type of study is a vital first step to developing new treatments for serious conditions like non-alcoholic steatohepatitis (NASH), a liver disease. By carefully studying how the medicine works in healthy volunteers, scientists can decide if it's safe and promising enough to continue testing in people who actually have NASH.
At a glance
What is this study about?
Imagine scientists are trying to build a completely new kind of car. Before they let anyone drive it on the road, they do lots of tests in a safe, controlled environment. This human study is a bit like that. It's the very first time a new medicine, called MK-7480, is being given to people, specifically healthy men. The main goal is to check how safe it is and how the body handles it.
The condition this medicine might eventually help with is called Non-alcoholic Steatohepatitis, or NASH. It's a type of liver disease that's not caused by drinking alcohol. In NASH, there's a build-up of fat in the liver, along with inflammation and damage. Over time, it can become quite serious, leading to liver scarring, which is called fibrosis, and even liver failure. Currently, treatment options for NASH are limited, so there's a real need for new and effective medicines.
Because this is an early-stage study, researchers are carefully giving different groups of men a single, increasing dose of the new medicine. They want to see what happens at different dose levels – how much of the medicine stays in the body, how long it stays there, and if there are any side effects. This careful step-by-step approach is crucial. If the medicine proves to be safe and manageable in healthy volunteers, it can then move on to later stages of testing, eventually involving people who actually have NASH, to see if it can help improve their condition.
Key takeaways
- This is a Phase 1 study, the very first time MK-7480 is given to people.
- The main goal is to check how safe the new medicine is in healthy men.
- It aims to find new treatments for a liver disease called NASH.
- Only healthy men aged 18 and over can take part.
- Participants will receive a single dose and be closely monitored.
- It's important to understand both potential risks and benefits.
Who may be eligible?
To take part in this study, you must be a man aged 18 or older. There is no upper age limit, meaning older men can also be considered.
Crucially, you must be in good overall health. This means you shouldn't have any major ongoing medical conditions, especially those affecting your liver, heart, or kidneys. The study is specifically looking for healthy volunteers because it's the first time this medicine is being given to people, and scientists need to see its effects without other health issues complicating things.
Other specific health checks will be done by the study doctors to make sure you are suitable. This might include blood tests, a physical exam, and checking your medical history to ensure your body can safely handle the medicine being tested.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you a man?
- Are you 18 years old or older?
- Are you generally healthy with no major ongoing medical conditions?
- Are you able to commit to overnight stays and follow-up visits?
What does participation involve?
If you decide to take part, you would receive a single dose of the new medicine, MK-7480. You would need to spend a number of days or overnights at the study clinic so that doctors and nurses can closely monitor you after you take the medicine. They will carry out various tests, such as blood samples, to see how your body handles the medicine.
After you leave the clinic, you might have a few follow-up visits or phone calls to check on your health. The total time you'd be involved in the study, from your first screening appointment to your last follow-up, would be made clear to you before you agree to take part.
Potential risks and benefits
Locations (1)
- —UnverifiedBelgium
Common questions
What is Non-alcoholic Steatohepatitis (NASH)?
NASH is a liver disease where you have fat in your liver, swelling, and damage, not caused by drinking too much alcohol. It can become serious over time.
Why is this study only for men?
Some early-stage studies are designed to test a new medicine in one group first, for safety, before eventually widening to include other groups like women or people with the condition.
Will I get paid for taking part?
Information about compensation for time and travel will be fully explained by the study team if payment is offered for your participation.
What does 'single ascending dose' mean?
It means different groups of healthy men will each receive one dose of the medicine. Each group will receive a slightly higher dose than the previous group, to carefully check safety at increasing levels.
Is MK-7480 already an approved medicine?
No, MK-7480 is a new, experimental medicine that has not been approved for any use yet. This study is the very first step in testing it in humans.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.